A vaccine antibody titer test measures antibodies to one specific vaccine antigen, such as hepatitis B surface antigen, measles virus, tetanus toxoid, or pneumococcal capsule. There is no single blood test that produces a universal “immunity score.” Each vaccine has its own assay, units, evidence standard, and clinical purpose. A positive IgG result may document prior vaccination or infection, while a quantitative result collected before and after a vaccine may test whether the immune system can produce antibodies. Even then, circulating antibody is only one part of protection: immune memory, T cells, antibody quality, mucosal defenses, age, exposure, and health conditions also matter. Some routine vaccine records are stronger evidence than a later negative commercial titer, particularly for measles, mumps, and varicella after documented doses. In other settings, such as selected hepatitis B post-vaccination testing, a defined antibody concentration is central. This article explains how to match the test to the question, interpret common antigen-specific results, avoid false conclusions, and decide whether vaccination, repeat testing, or immune evaluation is appropriate.
- Vaccine titers are antigen-specific; one result cannot describe protection against unrelated diseases.
- IgG generally reflects past exposure or vaccination, while IgM is usually used for suspected recent infection and is not a routine immunity marker.
- A written, age-appropriate vaccine record may supersede a negative commercial titer for selected vaccines.
- Paired pre- and post-vaccine samples assess antibody production more reliably than an isolated low baseline value.
- Passive antibodies, immune-suppressing treatment, timing, assay limitations, and natural waning can all change the result.
Table of Contents
- Define the question before ordering
- Understand IgG, IgM, units, and cutoffs
- When records are better than titers
- How common vaccine titers differ
- Testing the ability to make antibody
- Factors that distort or confound results
- What a low, negative, or equivocal result means
- Choose the next step by scenario
Define the question before ordering
The phrase “vaccine titer” is used for several different tasks. The correct test and interpretation depend on which task is intended.
The first task is documentation. A school, employer, health-care facility, immigration process, fertility clinic, pregnancy program, or travel service may require evidence of vaccination or laboratory evidence of immunity. The governing policy determines which records or assays are acceptable.
The second task is clinical protection assessment. A clinician may want to know whether measurable antibody is present after vaccination, especially in a person at increased risk from exposure. Hepatitis B surface antibody testing in selected health-care workers, dialysis patients, and infants born to infected mothers is a common example.
The third task is immune-function testing. An allergist-immunologist may measure antibodies before and after a vaccine to determine whether B cells can produce specific antibody. Protein antigens such as tetanus and diphtheria and polysaccharide antigens such as pneumococcal serotypes test overlapping but distinct pathways.
The fourth task is diagnosis of acute infection. This is not the same as an immunity titer. Measles, mumps, rubella, varicella, hepatitis, and other infections may require IgM, polymerase chain reaction, antigen testing, paired acute and convalescent samples, or other pathogen-specific studies. Ordering an “IgG/IgM immunity panel” without symptoms or exposure can create false-positive IgM results and unnecessary alarm.
Before testing, write down:
- the exact disease and vaccine;
- whether the goal is documentation, protection assessment, immune diagnosis, or acute-infection diagnosis;
- dates and products for previous doses;
- timing of recent blood products or immunoglobulin therapy;
- current immune-suppressing medicines;
- pregnancy status when relevant; and
- the rule or clinical guideline that will determine the next action.
This step prevents a common problem: ordering a result that cannot answer the practical question. For many healthy people with reliable vaccination records, no titer is needed.
Understand IgG, IgM, units, and cutoffs
IgG is the antibody class most often used to assess prior vaccination or past infection. It can remain detectable for years, but the concentration may decline even while immune memory persists. A negative IgG may indicate susceptibility, assay insensitivity, waning circulating antibody, incorrect timing, or immune dysfunction depending on the antigen.
IgM usually appears earlier during infection and declines sooner. It is not a general marker of vaccine protection. IgM can be falsely positive because of cross-reactivity, rheumatoid factor, nonspecific immune activation, or recent vaccination. Rubella IgM, for example, should not be included in routine screening of an asymptomatic pregnant person merely to assess immunity.
Assays can be qualitative, semiquantitative, or quantitative. A qualitative result may say positive, negative, reactive, nonreactive, or equivocal. A quantitative assay reports a concentration or index in units such as:
- milli-international units per milliliter for hepatitis B surface antibody;
- international units per milliliter for tetanus, diphtheria, or rubella antibody;
- micrograms per milliliter for pneumococcal serotype IgG; or
- an assay-specific antibody index for measles, mumps, or varicella IgG.
Units from different antigens cannot be compared. A value of 10 has no meaning without the antigen, units, method, and cutoff. Results from different laboratories may also be noninterchangeable because antigen preparations, calibration, detection systems, and reference populations differ.
A cutoff is usually chosen for a defined use. It may represent evidence of exposure, a correlate of reduced disease risk, or a statistical boundary between reference groups. It is rarely a perfect biological wall. Protection may vary by strain, serotype, immune status, and clinical endpoint.
The words “immune” and “protective” on a report should therefore be read as method-specific interpretations. They do not mean that infection is impossible. Vaccines often reduce disease severity and complications even when they do not create sterilizing immunity.
When records are better than titers
Vaccination policy often accepts more than one form of evidence: written vaccine documentation, laboratory evidence of immunity, laboratory confirmation of past disease, or—in selected settings—birth before a specified year. Which evidence applies depends on the disease and population.
For measles, mumps, and rubella, documented age-appropriate MMR doses are generally strong presumptive evidence of immunity. Routine serologic testing after documented vaccination is not recommended for most people. Commercial assays can return negative or equivocal results even when a vaccine response occurred.
For health-care personnel with two documented MMR doses, historical CDC guidance states that vaccination documentation supersedes later negative or equivocal measles or mumps titers. Additional MMR doses are not routinely given merely to convert such a test result. Current occupational policy and outbreak guidance should still be checked.
Varicella is another important example. Commercial IgG assays are useful for disease-induced immunity but may lack sensitivity for lower antibody levels after vaccination. Documented receipt of two varicella vaccine doses generally supersedes a subsequent negative commercial titer, and routine post-vaccination serology is not recommended.
Rubella has special reproductive implications. Rubella IgG is used to assess immunity before, during, and after pregnancy. In the United States, 10 IU/mL is a commonly used laboratory cutoff. MMR is a live vaccine and is not given during pregnancy; a susceptible person is typically vaccinated after pregnancy. People of childbearing potential with documented rubella-containing doses but an IgG result not clearly positive may receive one additional MMR dose, up to a maximum number specified in current guidance, without repeated serology.
Records can be retrieved from state or national immunization registries, pediatric practices, schools, pharmacies, military systems, occupational health departments, prior employers, and prenatal records. A verbal memory of vaccination may not satisfy institutional requirements.
When no reliable record exists, vaccination is often simpler than testing if there is no contraindication. Giving an extra MMR dose to a person who may already be immune is generally not harmful, while testing can add cost and ambiguous results. The clinician must still consider pregnancy, severe immunodeficiency, prior anaphylaxis, and other vaccine-specific precautions.
How common vaccine titers differ
Each antigen has its own interpretation. A few examples show why a generic titer rule is unsafe.
Hepatitis B surface antibody
Anti-HBs is measured in mIU/mL. A concentration of at least 10 mIU/mL, measured at the appropriate time after completion of a valid series, is considered evidence of vaccine response in defined settings. Post-vaccination testing is usually performed one to two months after the final dose when indicated.
Anti-HBs should not always be interpreted alone. Hepatitis B surface antigen and total antibody to hepatitis B core antigen distinguish vaccination from current or past infection. Vaccine-induced immunity produces anti-HBs without anti-HBc, whereas natural infection usually produces anti-HBc.
Antibody can wane below 10 mIU/mL in an immunocompetent documented responder while immune memory remains. Such a person may still have long-term protection and generally does not need periodic testing. Dialysis, occupational exposure, perinatal exposure, and immunocompromise have separate protocols.
Measles, mumps, rubella, and varicella IgG
A positive IgG can serve as laboratory evidence of immunity when records are absent. However, assay performance differs. Mumps IgG does not necessarily predict neutralizing protection, and a positive result cannot distinguish vaccine exposure from prior infection. Varicella tests may miss vaccine-induced antibody.
Rubella IgG has a more standardized role in pregnancy-related screening. Measles IgG may be used when presumptive evidence is absent and vaccination cannot be assumed, but documented vaccination often takes precedence.
Tetanus and diphtheria antibodies
These quantitative IgG tests can document a protein-antigen response. A tetanus level around 0.1 IU/mL is widely used as a practical seroprotection benchmark with common immunoassays, although some laboratories identify lower concentrations as evidence of any vaccine response. A single titer does not replace routine boosters or wound-management guidance.
Pneumococcal serotype antibodies
Pneumococcal testing produces multiple serotype-specific IgG values. The 0.35 micrograms/mL threshold used in conjugate-vaccine population studies and the approximately 1.3 micrograms/mL threshold often used in polysaccharide immune evaluations serve different purposes. Response breadth, fold increase, age, vaccine history, and assay-specific cutoffs all matter.
This diversity is the central lesson: a laboratory panel labeled “vaccine immunity” may combine results that require entirely different clinical rules.
Testing the ability to make antibody
In an immune-deficiency evaluation, the question is not simply whether antibody is present. The question is whether the person can generate an appropriate response after antigen exposure.
A planned vaccine challenge often follows these steps:
- Review infections, vaccine history, medicines, and prior antibody products.
- Measure quantitative IgG, IgA, and IgM and selected baseline antigen-specific antibodies.
- Administer a clinician-selected, age-appropriate vaccine when safe and indicated.
- Collect post-vaccine blood at the specified interval.
- Compare final concentrations and changes from baseline using the same laboratory method.
Protein-antigen testing commonly uses tetanus or diphtheria toxoid. These responses require B cells and T-cell help. Polysaccharide testing often uses pneumococcal serotypes after PPSV23 in people old enough to mount reliable T-cell-independent responses.
A preserved tetanus response does not prove normal pneumococcal polysaccharide response. People with specific antibody deficiency may have normal total immunoglobulins and normal protein-antigen responses but inadequate responses to many pneumococcal serotypes.
Fold rise must be interpreted with the baseline. A fourfold increase from an extremely low value can remain inadequate, while a highly protective baseline may not rise fourfold. Final level, fold change, response breadth, and clinical phenotype are considered together.
The test is most meaningful when there is a compatible history, such as recurrent bacterial sinusitis, otitis, pneumonia, or invasive infection. Frequent uncomplicated viral colds alone are less specific. Structural airway disease, allergy, asthma, aspiration, smoking, and cystic fibrosis can mimic antibody deficiency.
Testing should occur before immunoglobulin replacement whenever safely possible because infused donor IgG contains antibodies to many vaccine antigens. Once replacement begins, measured titers may mainly reflect the product rather than the patient’s own production.
A poor response is not the final diagnosis. Additional studies may include lymphocyte subsets, B-cell phenotyping, complement tests, protein-loss evaluation, medication review, and genetic testing. The pattern distinguishes primary from acquired immune dysfunction.
Factors that distort or confound results
Timing is one of the largest sources of error. Blood drawn immediately after vaccination may precede the full IgG response. Blood drawn years later measures persistence, not the original ability to respond. The correct interval varies by antigen and purpose.
Passive antibody can create a positive result without active immunity. Intravenous or subcutaneous immunoglobulin, immune globulin products, plasma, and some transfusions contain donor antibodies. The effect may last for months and can interfere with both serology and live-vaccine timing.
Immune-suppressing treatment can reduce response. B-cell-depleting therapies may prevent antibody production for months. Chemotherapy, transplant drugs, high-dose corticosteroids, selected biologics, hematologic cancers, advanced kidney disease, and severe malnutrition can also lower titers or shorten persistence.
Protein loss through nephrotic syndrome or protein-losing enteropathy can reduce circulating IgG even when production is intact. Albumin, urine protein, gastrointestinal symptoms, and the clinical timeline help identify this mechanism.
Age changes expected results. Infants can carry maternal IgG, which may look like immunity but declines during the first months of life. Young children respond poorly to pure polysaccharide antigens as a normal developmental feature. Older adults may have lower or less durable responses because of immune senescence.
Acute infection and recent vaccination can complicate IgM testing. A positive IgM may represent cross-reactivity, prolonged persistence, recent vaccine response, or true infection. Suspected acute disease should be tested with the pathogen-specific diagnostic algorithm, often including nucleic-acid testing.
Assay limitations matter. Commercial varicella IgG assays can be falsely negative after vaccination. Mumps IgG does not reliably quantify protection. Different pneumococcal platforms produce different values. A result near a cutoff may change category on repeat testing without a meaningful biologic change.
Specimen and documentation errors also occur. Missing collection dates, wrong units, unmatched pre- and post-vaccine laboratories, and uncertainty about which product was given can make a technically accurate result clinically uninterpretable.
What a low, negative, or equivocal result means
A negative result can mean no prior vaccination or infection. It can also mean antibody waned, the assay lacks sensitivity, the test was drawn too early, passive antibody has cleared, immune suppression prevented a response, or the cutoff is not appropriate for the clinical question.
An equivocal result lies near the assay decision boundary. It should not be converted mentally into “almost immune.” The relevant policy may treat it as negative, accept documented vaccination instead, recommend repeat testing, or recommend vaccination.
The response depends on the antigen:
- For hepatitis B in a person who requires documented post-vaccine response, anti-HBs below 10 mIU/mL triggers a protocol based on the number of prior doses and exposure risk.
- For measles or mumps after two documented MMR doses, a negative commercial titer may not override the vaccination record.
- For varicella after two documented doses, a negative commercial assay may be a false negative and routine retesting is not recommended.
- For rubella in a person who may become pregnant, the IgG result and documented doses guide preconception or postpartum vaccination decisions.
- For tetanus, a low level may prompt vaccination review but does not determine acute wound prophylaxis by itself.
- For pneumococcal immune testing, one low serotype is common; a broad paired response pattern is required.
A high result also has limits. It does not guarantee that infection is impossible, prove that every immune compartment works normally, or predict how long the level will persist. Very high values usually do not require treatment.
A low vaccine antibody result does not diagnose common variable immunodeficiency or another primary immune disorder. Diagnosis requires the infection or immune-dysregulation phenotype, quantitative immunoglobulins, properly timed functional testing, and exclusion of acquired causes.
The result should be repeated only when repetition can resolve a defined uncertainty. Rechecking every few months without a management plan creates noise and may lead to unnecessary doses.
Choose the next step by scenario
For school, work, or immigration documentation, obtain the exact written requirement before ordering. A vaccine record may be accepted and may be more reliable than post-vaccine serology. When laboratory proof is required, use the specified assay and provide the complete report.
For a healthy person with missing records, review whether vaccination can be given safely without testing. In many cases, completing the recommended series is simpler than trying to reconstruct immunity with several assays. Live vaccines require pregnancy and immune-status screening.
For hepatitis B occupational protection, follow the current exposure-risk protocol. Testing is most informative one to two months after the final valid dose. A documented adequate response can prevent confusion years later when antibody has waned.
For pregnancy planning, focus on rubella and varicella evidence according to current guidance. Live MMR and varicella vaccines are given before pregnancy or postpartum, not during pregnancy. IgM should not be used as a routine immunity screen in an asymptomatic person.
For recurrent bacterial infections, request an allergist-immunologist evaluation rather than purchasing a broad commercial “immunity panel.” The specialist can choose protein and polysaccharide antigens, coordinate pre- and post-vaccine timing, and interpret results with quantitative immunoglobulins.
For immunosuppressive therapy, vaccination and testing should be planned with the treating team. Ideally, indicated vaccines are administered before B-cell-depleting or transplant therapy when time allows. A low titer during treatment may reflect the medicine rather than a lifelong primary defect.
For a suspected acute vaccine-preventable infection, contact a clinician or public-health authority. Do not rely on an old IgG titer to rule out disease. Diagnostic specimens, isolation, post-exposure prophylaxis, and treatment may be time sensitive.
Patients can make any evaluation more accurate by keeping a durable record of vaccine product, lot when available, date, site, baseline result, post-vaccine result, units, laboratory, and any antibody-containing treatment. This record is more useful than the isolated label “immune.”
The best final interpretation is narrow and explicit: it states what antigen was measured, why it was measured, what the assay can support, and what it cannot prove. Vaccine titers are valuable when used for the right question; they become misleading when treated as a universal scorecard.
When policies and clinical recommendations differ, the treating clinician should document which standard was applied and why. This preserves a result’s meaning when employment, travel, pregnancy, exposure risk, or immune treatment changes later.
References
- Clinical Testing and Diagnosis for Hepatitis B. Centers for Disease Control and Prevention. 2025.
- Measles Vaccine Recommendations. Centers for Disease Control and Prevention. 2026.
- Varicella Vaccine Recommendations. Centers for Disease Control and Prevention. 2024.
- Serology Testing for Rubella. Centers for Disease Control and Prevention. 2024.
- Laboratory tests. Immune Deficiency Foundation. Accessed 2026.
- Laboratory tests, patient story critical in diagnosing PI. Immune Deficiency Foundation. 2024.
Disclaimer
This article is for general educational use and does not determine an individual’s immunity, vaccination schedule, occupational clearance, or diagnosis of immune deficiency. Assays, evidence requirements, and vaccine recommendations vary by antigen, setting, country, and health status, so results should be interpreted by a qualified clinician or the relevant public-health or occupational authority. Seek prompt medical advice after a significant exposure or when symptoms suggest an acute vaccine-preventable infection.
